Stryker Corporation (NYSE:SYK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Stryker Corporation (NYSE:SYK) has earned an average rating of “Moderate Buy” from the twenty-two brokerages that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $395.4762.

Several research firms have recently weighed in on SYK. Needham & Company LLC reduced their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. William Blair reissued an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Finally, TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th.

Stryker Stock Down 0.0%

Shares of SYK stock opened at $306.74 on Wednesday. Stryker has a 1 year low of $281.00 and a 1 year high of $404.87. The stock has a market cap of $117.59 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. The business’s fifty day moving average is $329.68 and its 200-day moving average is $351.50. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

Several hedge funds and other institutional investors have recently modified their holdings of SYK. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the fourth quarter worth $26,000. Sankala Group LLC acquired a new stake in shares of Stryker in the fourth quarter worth $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the third quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the fourth quarter worth $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.